Drugs & Targets FDA approves darolutamide for non-metastatic castration-resistant prostate cancer August 02, 2019Vol.45 No.31
Drugs & Targets FDA grants breakthrough designation for NKTR-214 in combination with nivolumab for melanoma August 02, 2019Vol.45 No.31
Drugs & Targets EMA adopts positive opinion for Keytruda + Inlyta as first-line for RCC August 02, 2019Vol.45 No.31
Trials & Tribulations Barriers to clinical trial enrollmentPart I of a two-part series August 02, 2019Vol.45 No.31By Daniel Wall, Stephanie Engelien and Adedayo A. Onitilo
In Brief ACS CAN report: Texas must improve cancer-related public policies August 02, 2019Vol.45 No.31
In Brief TCR2 Therapeutics partners with NCI for phase I/II trial of TC-210 August 02, 2019Vol.45 No.31
MD Anderson retains top spot on U.S. News rankings; Johns Hopkins moves up to No. 4 August 02, 2019Vol.45 No.31By Matthew Bin Han Ong
